Research Analysts Offer Predictions for ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities research analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Arcturus Therapeutics in a report issued on Tuesday, August 12th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the biotechnology company will post earnings of ($3.02) per share for the year, up from their previous forecast of ($3.10). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. Cantor Fitzgerald also issued estimates for Arcturus Therapeutics’ FY2026 earnings at ($3.77) EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.77. The company had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%.

Several other research analysts also recently weighed in on ARCT. Wells Fargo & Company decreased their price target on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating on the stock in a research report on Tuesday. Citigroup reiterated a “buy” rating and issued a $49.00 price target (up from $47.00) on shares of Arcturus Therapeutics in a research report on Tuesday. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Canaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Finally, Scotiabank reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $50.00.

Arcturus Therapeutics Stock Up 0.1%

NASDAQ:ARCT opened at $19.23 on Thursday. The company’s 50 day moving average price is $13.44 and its 200-day moving average price is $13.31. Arcturus Therapeutics has a 52 week low of $8.04 and a 52 week high of $25.88. The stock has a market cap of $522.29 million, a price-to-earnings ratio of -8.62 and a beta of 2.26.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ARCT. Byrne Asset Management LLC increased its position in Arcturus Therapeutics by 89.8% during the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 1,365 shares during the last quarter. US Bancorp DE boosted its stake in Arcturus Therapeutics by 218.9% during the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,329 shares during the period. Virtus ETF Advisers LLC boosted its stake in Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after buying an additional 1,132 shares during the period. Strs Ohio purchased a new position in Arcturus Therapeutics during the first quarter worth about $89,000. Finally, Russell Investments Group Ltd. boosted its stake in Arcturus Therapeutics by 40,686.2% during the first quarter. Russell Investments Group Ltd. now owns 11,828 shares of the biotechnology company’s stock worth $125,000 after buying an additional 11,799 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.